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Focus Issue: Aspirin
Aspirin was originally synthesized more than 100 years ago and more than 50,000tons are produced every year, yet the seven articles in this mini-focus show that
several questions remain unanswered regarding the use of aspirin for the treatment or
prevention of cardiovascular disorders. Masoudi and colleagues report that in 24,000
Medicare beneficiaries with a history of coronary artery disease (CAD) and heart
failure, aspirin was prescribed in only about 50% of patients and was associated with a
slight mortality reduction. A viewpoint by Massie reviews the literature on aspirin use
and systolic dysfunction and concludes that it probably increases fluid retention and
thus the readmission rate for heart failure exacerbations, but has no effect on hard
cardiovascular end points. He suggests that therapy should be individualized based on
the patient’s risk for recurrent thrombosis. Previous studies have shown that patients
who have been taking aspirin and then go on to a myocardial infarction have worse
outcomes. Portnay and colleagues challenge this assessment in their findings from a
large Medicare database where prior aspirin use was associated with lower one- and
six-monthmortality rates.Hermida and colleagues report that the physiologic effects of
aspirin have substantial circadian variation. Administration at night produced a sus-
tained blood pressure reduction, while morning dosing led to a slight elevation in
ambulatory blood pressure; overall a 10 mm Hg difference in average systolic blood
pressurewas observed.An editorial byMesserli examines thebiologic plausibility of this
finding and cautions against recommending an immediate change to night-time
dosing. Previous trials and physiologic models have suggested that aspirin may antag-
onize the effectiveness of angiotensin-converting enzyme inhibitors, yet themajority of
cases of systolic dysfunction are secondary to CAD. Mason and colleagues present a
state-of-the-art paper on aspirin resistance, including the need for a standardized
definition and the various factors that may account for the resistance. A paper by
Hoefer and colleagues reports that aspirin inhibited the formation of new collateral
vessels in an animal model of chronic ischemia while clopidogrel did not, suggesting
that inhibition of cyclooxygenase limits collateral formation. In summary, this mini-
focushighlights someof the lingeringquestions regarding theuse of aspirinuse thatwill
need to be addressed in the next 100 years. See pages 955, 963, 967, 975, 984,
986, and 994. See figure.
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Heart Failure and
Cardiac Transplant
Impaired Endothelial Function Increases Risks for Subjects With CHF
Studies suggest that congestive heart failure (CHF) alone can result in endothelialdysfunction through decreased peripheral blood flow, cytokine activation, in-
creased oxidative stress, and elevated endothelin levels. Meyer and colleagues assessed
brachial artery flow-mediated vasodilation (FMD) in 75 subjects with symptomatic
CHF and ejection fraction30%; they then followed these patients for three years to
determine clinical outcomes. Impaired FMD was found to be a significant and
independent predictor of adverse cardiovascular outcomes. This study suggests that
FMD is a powerful risk stratifier for subjects withCHF andmay be useful as a target of
intervention in future trials. See page 1011. See figure.
Cardiac Rhythm Disorders
Ectopic Atrial Beats That Originate Outside of the Pulmonary Veins
May Trigger Atrial Fibrillation
Pulmonary vein (PV) isolation can dramatically decrease the frequency of paroxys-mal atrial fibrillation (PAF) episodes, but a substantial number of patients con-
tinue tohave recurrences.When theprocedure is successful, it isolates ectopic beats that
are initiated in the PVs from reaching the rest of the atria. Lee and colleagues have
previously shown that in some patients the triggering beat begins in locations other
than the PVs; isolating the PVs would thus have no effect on the frequency of PAF. In
this study they report on the patient characteristics that are associated with triggering
beats outside of the PVs. Females are twice as likely to have triggering beats originate in
the superior vena cava; patients with left atrial enlargement may have triggering beats
from the posterior wall of the left atrium. These findings may eventually be useful in
personalizing ablation techniques. See page 1054.
Cardiac Imaging
A Nuclear Tracer to Distinguish Between Types of Cardiac Amyloidosis
Two major types of amyloidosis can lead to heart failure; differentiating betweenthem clinically is difficult, but has prognostic importance. Hereditary amyloid-
osis is usually caused by amutation in the transthyretin or the fibrinogenA alpha-chain
protein; the primary therapy is combined heart and liver transplantation. Systemic
amyloidosis is caused by a plasma cell dyscrasia; therapy involves chemotherapywith or
without bone marrow transplantation. Previous attempts to use nuclear scintigraphy
for the diagnosis of cardiac amyloidosis have shown discrepant results. Perugini and
colleagues hypothesized that this discrepancy may result from differential imaging
characteristics between the two types of amyloidosis. They report that the cardiac
uptake of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid is much higher
for patients with hereditary amyloidosis and had 100% accuracy for differentiating
the two types. See page 1076.
